SIONNA THERAPEUTICS INC. - COMMON STOCK

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

27 Aug 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

25 Aug 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

11 Aug 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

06 Jun 2025 08:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

04 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

03 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

22 May 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics Reports First Quarter 2025 Financial Results

12 May 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

30 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

20 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

24 Feb 2025 05:00:52 By Nasdaq GlobeNewswire